Allogene Therapeutics, Inc.ALLONASDAQ

Revenue (LTM)

-100.0% YoY

Net Income (LTM)

$-191M

+25.9% YoY

Free Cash Flow

$-150M

Revenue CAGR (5Y)

—

Marginsimproving

FCF($0.1B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	114	0↓99.9%	0↓39.1%	0↓76.8%	0
Gross Profit	114	-14↓112.4%	0↑100.7%	0↓76.8%	-12↓56277.3%
Operating Income	-180	-336↓86.2%	-328↑2.3%	-273↑16.6%	-207↑24.3%
Net Income	-182	-340↓87.0%	-327↑3.9%	-258↑21.3%	-191↑25.9%
EBITDA	-170	-321↓89.3%	-313↑2.5%	-243↑22.3%	-195↑20.0%
EPS Diluted	-1.34	-2.38↓77.6%	-2.09↑12.2%	-1.32↑36.8%	-0.87↑34.1%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	173	62↓64.3%	83↑34.3%	75↓9.5%	52↓31.3%
Total Current Assets	471	529↑12.2%	459↓13.2%	303↓33.9%	258↓15.0%
Total Assets	1,051	822↓21.8%	643↓21.8%	549↓14.6%	416↓24.2%
Total Current Liabilities	48	54↑12.2%	37↓31.0%	36↓4.2%	33↓8.5%
Total Liabilities	126	155↑23.1%	131↓15.6%	127↓3.1%	123↓2.5%
Total Equity	925	667↓27.9%	512↓23.2%	422↓17.6%	293↓30.7%
Total Debt	73	101↑38.3%	95↓5.9%	91↓4.6%	75↓17.3%
Net Debt	-100	39↑139.1%	12↓69.5%	16↑29.9%	23↑50.3%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-185	-221↓19.3%	-238↓7.8%	-200↑15.7%	-149↑25.5%
Capital Expenditure	-21	-5↑75.8%	-2↑70.8%	-1↑54.2%	-0↑44.4%
Free Cash Flow	-206	-226↓9.4%	-239↓6.0%	-201↑16.0%	-150↑25.6%
Stock-Based Comp	81	84↑3.4%	66↓21.1%	52↓21.5%	38↓27.3%
Net Change in Cash	-9	-111↓1111.8%	21↑119.1%	-8↓137.3%	-24↓196.5%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance